Hepion Pharmaceuticals In...

NASDAQ: HEPA · Real-Time Price · USD
0.07
0.01 (22.59%)
At close: Jun 09, 2025, 3:45 PM

Hepion Pharmaceuticals Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
n/a 109.73K 109.73K 109.73K 109.73K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost of Revenue
30.76K 43.02K 61.52K 79.85K 67.13K 73.34K 72.57K 72.77K 77.46K 82.4K 87.78K 90.66K 86.07K 62.66K 39.55K 18.14K
Gross Profit
-30.76K 66.71K 48.21K 29.88K 42.6K -73.34K -72.57K -72.77K -77.46K -82.4K -87.78K -90.66K -86.07K -62.66K -39.55K -18.14K
Operating Income
-19.35M -28.55M -34.76M -40.42M -48.45M -47.81M -45.61M -51.45M -45.49M -44.72M -44.77M -31.62M -30.4M -26.36M -24.07M -21.99M
Interest Income
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Pretax Income
-16.16M -26.08M -31.74M -41.9M -49.34M -47.56M -45.58M -51.41M -45.08M -45.12M -45.84M -33.6M -32.73M -27.96M -24.98M -22.16M
Net Income
-13.19M -22.7M -28.37M -38.52M -48.93M -44.68M -42.7M -48.53M -42.2M -45.12M -45.84M -33.6M -32.73M -27.96M -24.92M -22.19M
Selling & General & Admin
7.47M 7.45M 7.9M 8.82M 9.62M 8.23M 8.81M 8.95M 8.48M 10.18M 10.17M 10.42M 10.01M 10.24M 9.98M 9.13M
Research & Development
11.85M 17.88M 23.64M 28.38M 35.64M 37.71M 34.93M 38.76M 33.27M 32.66M 32.72M 21.21M 20.4M 16.11M 14.09M 12.86M
Other Expenses
n/a 3.19M 3.19M 3.19M 3.19M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Operating Expenses
19.32M 25.33M 31.54M 37.2M 45.26M 45.94M 43.74M 47.7M 41.75M 42.84M 42.9M 31.62M 30.4M 26.36M 24.07M 21.99M
Interest Expense
4.35K 6.76K 6.76K 9.11K 7.08K 7.18K 9.45K 10.28K 10.16K 9.83K 9.7K 9.01K 8.86K 21.75K 35.77K 33.28K
Selling & Marketing Expenses
-30.76K -30.76K -30.76K -30.76K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
19.35M 25.36M 31.57M 37.23M 45.26M 45.94M 43.74M 47.7M 41.75M 42.84M 42.9M 31.62M 30.4M 26.36M 24.07M 21.99M
Income Tax Expense
-2.97M -3.38M -3.52M -3.51M -541.97K -3.02M -2.8M -2.8M -2.8M 89.83K 9.7K 9.01K 8.86K 3.73K -60.44K 32.64K
Shares Outstanding (Basic)
139.17K 134K 115K 101K 88K 76K 76K 76K 52K 76K 76K 76K 76K 76K 76K 52K
Shares Outstanding (Diluted)
139.17K 134.38K 115.98K 101.45K 88.13K 76.77K 76.53K 76.23K 76.23K 76.23K 76.23K 76.23K 76.29K 76.22K 76.22K 52.16K
EPS (Basic)
-110.77 -223.67 -324.59 -474.72 -620.54 -625.56 -600.56 -677.79 -594.75 -591.67 -601.15 -440.54 -465.88 -632.96 -511.35 -410.76
EPS (Diluted)
-110.77 -223.67 -324.59 -474.72 -620.54 -625.56 -600.56 -677.79 -594.75 -591.67 -601.15 -440.54 -465.88 -632.96 -511.35 -410.76
EBITDA
-15.52M -30.2M -36.39M -42.04M -49.49M -47.71M -45.51M -51.25M -44.92M -44.95M -45.74M -33.49M -32.63M -27.85M -24.88M -22.07M
EBIT
-15.55M -30.25M -36.45M -42.12M -49.55M -47.78M -45.58M -51.32M -44.99M -45.03M -45.83M -33.59M -32.71M -27.93M -24.94M -22.12M
Depreciation & Amortization
30.76K 43.02K 61.52K 79.85K 67.13K 73.34K 72.57K 72.77K 77.46K 82.4K 87.78K 90.66K 86.07K 76.24K 60.34K 46.13K